VolitionRx Limited to Present at Conferences in March 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Cantor Fitzgerald Starts VolitionRX (VNRX) at Overweight
March 9, 2021 4:08 PM ESTCantor Fitzgerald analyst Kyle Mikson initiates coverage on VolitionRX (NYSE: VNRX) with a Overweight rating and a price target of $8.00.
The analyst comments "We are initiating coverage of VolitionRx (VNRX) with an Overweight rating and a 12-month price target of $8. The company is developing a suite of blood-based (liquid... More
